Determination of non-treatment with statins of high risk patients in the Netherlands

Current Medical Research and Opinion

Volumn 26, Issue 2, 2010, Pages 271-278

  Van Den Haak, Pieter ^a   Heintjes, Edith ^a   Plat, Arian W ^a   Jan Meerding, Willem ^b   Webb, Kate ^c   Sturkenboom, Miriam C ^d   Herings, Ron M C ^d  

^a PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^b PFIZER INC   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cardiovascular disease; Diabetes; Observational study; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG USE; FEMALE; HEART ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; NON INSULIN DEPENDENT DIABETES MELLITUS; SEX DIFFERENCE; SOCIAL STATUS;

ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NETHERLANDS; RISK FACTORS;

EID: 74549130119     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903435184     Document Type: Article

References (19)

1. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003;24:1601-1610
2. Smith Jr SC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113:2363-2372
3. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-1278
4. Erkelens DW. [Cholesterol consensus in The Netherlands]. Ned Tijdschr Geneeskd 1987;131:1564-1569
5. Erkelens DW. [Revision of consensus cholesterol]. Ned Tijdschr Geneeskd 1991;135:2337-2340
6. Miller M, Byington R, Hunninghake D, et al. Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) Investigators. Arch Intern Med 2000;160:343-347
7. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554-572
8. Mantel-Teeuwisse AK, Klungel OH, Hofman A, et al. Prescribing behaviour according to Dutch and European guidelines on the management of hyperch-olesterolaemia (1992-1999). Br J Clin Pharmacol 2006;61:592-600
9. Kamal-Bahl SJ, Burke T, Watson D, et al. Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol 2007;99:530-534
10. van der Lei J, Duisterhout JS, Westerhof HP, et al. The introduction of computer-based patient records in The Netherlands. Ann Intern Med 1993;119:1036-1041
11. Vlug AE, van der Lei J, Mosseveld BM, et al. Postmarketing surveillance based on electronic patient records: the IPCI project. Methods Inf Med 1999;38:339-344
12. Hofmans-Okkes IM, Lamberts H. The International Classification of Primary Care (ICPC): new applications in research and computer-based patient records in family practice. Fam Pract 1996;13:294-302
13. International Publication Series Health, Welfare and Sport no.19. The Hague, Netherlands: Ministry of Health, Welfare and Sport;2004 July 2004
14. van den Berg Jeths A, Baan CA. Prestatie-indicatoren voor de preventie en zorg bij diabetes [Performance indicators for the prevention and care of diabetes]. Bilthoven: RIVM; 2006. Report No.: 270551008/2006
15. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998;279:1458-1462
16. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA 2002;288:2880-2883
17. Goettsch WG, Yin DD, Alemao E, et al. Statins are less effective in common daily practice among patients with hypercholesterolemia: the REALITY-PHARMO study. Curr Med Res Opin 2004;20:1025-1033
18. Penning-van Beest FJ, Termorshuizen F, Goettsch WG, et al. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J 2007;28:154-159
19. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 1996;164:208-211